Next Phase Newsletter

A publicly listed large pharma company in China is seeking strategic partnerships which can be in the form of licensing, equity, or acquisition of the asset. The firm’s typical investment depends on the technology, with a max investment of $10M – $15M per company. The firm is primarily seeking companies at growth and pre-IPO stages in fields of pharmaceuticals, biotechnology, and medical devices who have a strategic angle towards China. The firm invests in companies based in the U.S., China, Europe, and potentially South Korea and Israel.

The firm prioritizes biotechnology pharmaceuticals, with secondary interests in medical devices that produce high-value consumables and tertiary interests in diagnostic companies. The firm is not interested in companies that manufacture large medical equipment, such as MRI machines. For purely innovative technology, the firm will look as early as preclinical stage for those with high likelihood to succeed in clinics. In terms of indication, the firm prioritizes diabetes, cardiovascular, infectious disease, orthopedics, and oncology opportunities. However, the firm will look at indications outside of these areas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity firm based in Beijing, China with total asset under management of over US$1 billion seeks early to growth stage opportunities that are suitable for the China market and invests across several industry sectors including healthcare. The firm also partners with public enterprises in China on M&A and licensing opportunities. Typical equity investments range from 10 million to 4 billion RMB (US$1.5 to 600 million). The firm is now looking for opportunities in China, Israel, the US, and Canada.

Within healthcare, the firm is interested in therapeutic products in cardiovascular, psychiatry, and oncology. The firm prefers clinical stage projects from phase I to IIa trials, and is opportunistic in terms of modality. The firm is also interested in medical devices in ophthalmology and orthopedics that have at least obtained prototype and clinical validation.

The firm is looking for products with a China angle.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the US Midwest invests in high-technology start-up and early stage companies in the Midwest region. The firm prefers to be the lead investor and seeks first round investments of $1-2M. The firm is actively seeking new investment opportunities.

The firm is currently seeking to invest in early stage IT companies, including medical IT companies such as medical device software and software platforms. Although the firm is currently focused on medical IT, the firm may consider exceptional medical devices with a 510(k)-regulatory pathway.

The firm only invests in companies that are based in the Midwest region, primarily in Pennsylvania, Ohio and Michigan. The firm prefers to be the first institutional investor and requests a board seat in each portfolio company. The firm seeks a company with a driven entrepreneurial management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A healthcare asset management institution based in Beijing, China manages more than 20 healthcare equity investment funds and is currently investing from its US$50 million fund focusing on early stage opportunities from North America. The firm prefers to follow a syndicate in Angel and Pre-Series A rounds. Typical investment ranges from US$0.5 to 1 million.

The firm is interested in medical devices and diagnostic technologies that have large market potential in China. The firm prefers products in pre-clinical and clinical development stage. The firm is agnostic to indication areas.

The firm is looking for experienced management teams with strong sector knowledge. Leveraging its network and portfolio companies, the firm can assist with finding local registration and distribution partners and may request regional rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment firm that administers four evergreen life science investment funds is making investments in both privately held and publicly traded life science companies. In general the funds can only invest in US-based companies. The firm makes an average of 4 new early stage life science investments each year, and initial investments are typically $6-10m initially with the potential for further investment in follow-on rounds. The firm invests at a wide range of developmental stages, typically from Series B through to IPOs and PIPEs.

The funds are extremely opportunistic within the life science sector, and consider opportunities in drug development, medical devices and healthcare IT. The funds prefers to invest in companies with clinical data but will also consider preclinical opportunities.

The funds invest in both privately held and publicly traded companies. The firm only invests in management teams that have relevant industry experience, preferring not to work with new entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A strategic consulting firm has formed a new venture capital arm with offices based in Minneapolis and Shanghai, China. Alongside investments, the firm advises life science companies on strategic partnerships (manufacturers, distributors) in the China market by providing resources in the network. The firm’s first fund is predicted to close end of 2016. The firm is seeking five new investments within the next year, and typically makes $1M – $5M dollar investments per company in Series B and C rounds, but also considers Series A. The firm acts as co-investors while also helping companies seek additional investors for the round. The firm focuses on US and Canada based companies, though is open to companies on a global-level.

The firm is indication agnostic and open to technology in all sectors of life science – medical devices, therapeutics, diagnostics, and healthcare IT – while having the most experience in biotech/medtech. In terms of phase of development, the firm requires the company to at least have a prototype, and for therapeutics to be in clinical trials, preferably in Series B. The firm will also look at on-the-market products as well as lab equipment and drug development enabling technology.

The firm requires the company to be in Series A, B, or C. The firm prefers the company to have or seek to have their technology in the China market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A specialized investment firm is currently investing from its third oncology fund of USD 64 million. The firm generally makes investments in Series A, B or C equity rounds; the firm is not interested in seed rounds. The firm typically makes allocations of $3-8 million, and may either lead investments or act as a co-investor alongside a syndicate. The firm is open to oncology opportunities globally but has recently invested primarily in the USA.

The firm is currently focused on cancer therapeutics. The firm will consider any form of therapeutic molecule in oncology, including small molecules, antibodies or new technologies such as cell therapies. The firm generally invests at the late preclinical stage, from 6-12 months pre-IND, but is also interested in companies with Phase I or Phase II assets.

The firm places high importance on the management team’s scientific rigor and industry experience; the firm prefers to work with entrepreneurs who have led biotech companies previously. The firm also considers the strength of the investor syndicate and their alignment of interests.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com